logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Keiko Tanimura

fukuchiyama city hospital
H指数:13
被引数:1,060

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regimen selection for combined immunotherapy in non-small cell lung cancer with PD-L1 < 1%: a multicenter, retrospective study from Japan (SPIRAL-LT1)

PD-L1<1%的非小细胞肺癌联合免疫治疗方案选择：一项来自日本的多中心回顾性研究（SPIRAL-LT1）

Scientific Reports
IF3.9
2026-10-160
OAAI
Daiki Murata; Koichi Azuma; Kenta Murotani; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Naoya Nishioka; Tadaaki Yamada; Koichi Takayama
Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease

基线中性粒细胞与淋巴细胞比率可预测间质性肺病患者开始使用nintedanib后的生存时间

BMC Pulmonary Medicine
IF2.8
2026-05-190
OAAI
Shiho Goda; Tadaaki Yamada; Yasuhiro Goto; Sayaka Uda; Akira Nakao; Shinsuke Shiotsu; Yuji Kukida; Keiko Tanimura; Akifumi Miyamoto; Yuki Imasato; Asuka Okada; Isao Hasegawa; Koji Date; Yohei Matsui; Shoki Morito; Noeru Inokuchi; Shuji Osugi; Hayato Kawachi; Naoya Nishioka; Masahiro Iwasaku; Shinsaku Tokuda; Tomohiro Handa; Koichi Takayama
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria

识别PD-L1高表达非小细胞肺癌中隐藏恶病质亚组：AWGC与Fearon标准的比较分析

journal of cachexia, sarcopenia and muscle
IF0
2026-04-120
OAAI
Naoya Nishioka; Hayato Kawachi; Tadaaki Yamada; Motohiro Tamiya; Yoshiki Negi; Yasuhiro Goto; Akira Nakao; Shinsuke Shiotsu; Keiko Tanimura; Takayuki Takeda; Asuka Okada; Taishi Harada; Koji Date; Yusuke Chihara; Isao Hasegawa; Nobuyo Tamiya; Takeo Ogawa; Masahiro Iwasaku; Shinsaku Tokuda; Takashi Kijima; Koichi Takayama
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy

基于炎症选择最优免疫疗法：用于PD-L1 ≥50%基因突变阴性IV期非小细胞肺癌：帕博利珠单抗单药治疗与联合化疗免疫疗法

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-11-300
PRE
Kunimatsu, Yusuke; Nishioka, Naoya; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Ishida, Masaki; Kijima, Takashi; Takayama, Koichi
Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study

肺癌免疫预后指数在PD-L1低表达/阴性肿瘤的非小细胞肺癌患者接受化疗免疫治疗中的影响：一项真实世界多中心回顾性研究

ESMO Open
IF8.3
2025-11-200
OAAI
A. Yoshimura; T. Takeda; K. Tanimura; Y. Chihara; H. Kawachi; Y. Yamanaka; N. Tamiya; R. Honda; T. Yamada; K. Uryu; S. Shiotsu; H. Yoshioka; T. Yamada; T. Kurata; K. Takayama
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

免疫检查点抑制剂诱导的间质性肺病（合并与不合并CTLA-4方案）在PD-L1 < 1 %的非小细胞肺癌患者中的研究：一项多中心、回顾性研究

Lung Cancer
IF4.4
2025-09-260
PRE
Daiki Murata; Koichi Azuma; Kenta Murotani; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Naoya Nishioka; Tadaaki Yamada; Koichi Takayama
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ramucirumab与erlotinib联合作为携带<i>EGFR</i>外显子21 L858R突变的晚期或复发非小细胞肺癌的一线治疗：一项在日本进行的多中心回顾性观察队列研究（REAL-SPEED）。

Therapeutic Advances in Medical Oncology
IF4.2
2025-06-160
OA
Masashi Ishihara; Takahisa Kawamura; Yukiko Namba; Yuki Takeyasu; Yukihiro Hasegawa; Yuki Sato; Yoshiki Negi; Tomohiro Oba; Toshiyuki Sumi; Hirokuni Hirata; Hidemitsu Funabashi; Yuko Oya; Hajime Kikuchi; Naoko Katsurada; Takeshi Nakatani; Keiko Tanimura; Taku Nakagawa; Naoya Takeda; Takahiro Asami; Osamu Honjo; Hiromi Nagashima; Takumi Yamaura; Norihiko Hata; Miyako Kitazono; Naoya Nishioka; Akihiro Tamiya; Yuichi Sakamori; Ryota Shigaki; Kyoichi Kaira; Ryoichi Honda; Takashi Matsui; Eriko Suzuki; Kentaro Ito; Kojiro Otsuka; Naoto Takase; Yusuke Murakami; Kazuhiko Matsuno; Sumito Inoue; Akira Kisohara; Sojiro Kusumoto; Hiroe Aoshima; Yumiko Kakizaki; Akihito Kubo; Akito Hata; Nobuhisa Ishikawa; Kosuke Hamai; Nobuhiro Kanaji; Toshihiro Misumi; Noriyuki Matsutani; Nobuhiko Seki
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
ONCOIMMUNOLOGY
IF6.3
2024-12-160
OAAI
Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Kijima, Takashi; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Shimose, Takayuki; Takayama, Koichi
The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%

PD-L1表达为1%至49%的NSCLC患者中，抗生素使用对ICI联合化疗与化疗的影响

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Toyota, Y.; Hata, T.; Yamada, T.; Goto, Y.; Kijima, T.; Watanabe, S.; Furuya, N.; Oba, T.; Ikoma, T.; Nakao, A.; Tanimura, K.; Taniguchi, H.; Yoshimura, A.; Fukui, T.; Murata, D.; Kaira, K.; Shiotsu, S.; Hibino, M.; Okada, A.; Takayama, K.
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1%to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

TTF-1表达对PD-L1表达水平为1%至49%的非小细胞肺癌患者预后预测的影响：化疗与化疗免疫治疗的多中心回顾性研究

CANCER RESEARCH AND TREATMENT
IF3.8
2024-10-250
OA
Nishioka, Naoya; Hata, Tae; Yamada, Tadaaki; Goto, Yasuhiro; Amano, Akihiko; Negi, Yoshiki; Watanabe, Satoshi; Furuya, Naoki; Oba, Tomohiro; Ikoma, Tatsuki; Nakao, Akira; Tanimura, Keiko; Taniguchi, Hirokazu; Yoshimura, Akihiro; Fukui, Tomoya; Murata, Daiki; Kaira, Kyoichi; Shiotsu, Shinsuke; Hibino, Makoto; Okada, Asuka; Chihara, Yusuke; Kawachi, Hayato; Kijima, Takashi; Takayama, Koichi
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
INVESTIGATIONAL NEW DRUGS
IF2.7
2024-08-210
PRE
Tachibana, Yusuke; Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
FRONTIERS IN IMMUNOLOGY
IF5.9
2024-07-150
OAAI
Nishioka, Naoya; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Masui, Taiki; Sai, Natsuki; Ishida, Masaki; Katayama, Yuki; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2024-03-010
OA
Katayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Fujii, Hiroyuki; Morita, Satomi; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Hiranuma, Osamu; Yamada, Takahiro; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Iwasaku, Masahiro; Tokuda, Shinsaku; Tanaka, Noriyuki; Miyagawa-Hayashino, Aya; Takayama, Koichi
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

免疫检查点抑制剂联合化疗对TPS ≥ 50% 的老年非小细胞肺癌PD-L1预后的影响

FRONTIERS IN IMMUNOLOGY
IF5.9
2024-02-232
OAAI
Takei, Shota; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study
FRONTIERS IN ONCOLOGY
IF3.3
2024-01-260
OAAI
Yoshimura, Akihiro; Takeda, Takayuki; Kataoka, Nobutaka; Tanimura, Keiko; Fukui, Mototaka; Chihara, Yusuke; Takei, Shota; Kawachi, Hayato; Nakanishi, Kentaro; Yamanaka, Yuta; Tamiya, Nobuyo; Honda, Ryoichi; Okura, Naoko; Yamada, Takahiro; Uryu, Kiyoaki; Murai, Junji; Shiotsu, Shinsuke; Yoshioka, Hiroshige; Yamada, Tadaaki; Kurata, Takayasu; Takayama, Koichi
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
TARGETED ONCOLOGY
IF4
2023-10-302
PRE
Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Nishioka, Naoya; Katayama, Yuki; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS I50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Kawachi, H.; Yamada, T.; Tamiya, M.; Negi, Y.; Goto, Y.; Nakao, A.; Shiotsu, S.; Tanimura, K.; Takeda, T.; Okada, A.; Harada, T.; Date, K.; Chihara, Y.; Hasegawa, I.; Tamiya, N.; Iwasaku, M.; Tokuda, S.; Kijima, T.; Takayama, K.
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2023-04-015
OA
Katayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Fujii, Hiroyuki; Morita, Satomi; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Hiranuma, Osamu; Yamada, Takahiro; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Yoshimura, Akihiro; Iwasaku, Masahiro; Tokuda, Shinsaku; Kim, Young Hak; Takayama, Koichi
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

ALK重排肺癌中通过EGFR信号传导对lorlatinib的适应性耐药

NPJ PRECISION ONCOLOGY
IF8
2023-01-2618
OAAI
Katayama, Yuki; Yamada, Tadaaki; Tanimura, Keiko; Tokuda, Shinsaku; Morimoto, Kenji; Hirai, Soichi; Matsui, Yohei; Nakamura, Ryota; Ishida, Masaki; Kawachi, Hayato; Yoneda, Kazue; Hosoya, Kazutaka; Tsuji, Takahiro; Ozasa, Hiroaki; Yoshimura, Akihiro; Iwasaku, Masahiro; Kim, Young Hak; Horinaka, Mano; Sakai, Toshiyuki; Utsumi, Takahiro; Shiotsu, Shinsuke; Takeda, Takayuki; Katayama, Ryohei; Takayama, Koichi
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features

HER3激活有助于具有间充质特征的ALK重排肺癌中ALK抑制剂耐受细胞的出现

NPJ PRECISION ONCOLOGY
IF8
2022-01-1818
OAAI
Tanimura, Keiko; Yamada, Tadaaki; Okada, Koutaroh; Nakai, Kunihiro; Horinaka, Mano; Katayama, Yuki; Morimoto, Kenji; Ogura, Yuri; Takeda, Takayuki; Shiotsu, Shinsuke; Ichikawa, Kosuke; Watanabe, Satoshi; Morimoto, Yoshie; Iwasaku, Masahiro; Kaneko, Yoshiko; Uchino, Junji; Taniguchi, Hirokazu; Yoneda, Kazue; Matoba, Satoaki; Sakai, Toshiyuki; Uehara, Hisanori; Yano, Seiji; Kusaba, Tetsuro; Katayama, Ryohei; Takayama, Koichi

研究方向

暂未获取到该数据
T
Tadaaki Yamada
H 指数:41论文数:563被引数:6,292
K
Koichi Takayama
H 指数:75论文数:954被引数:1.9万
S
Shinsuke Shiotsu
H 指数:17论文数:121被引数:1,392
T
Takayuki Takeda
H 指数:22论文数:196被引数:2,736
Y
Yusuke Chihara
H 指数:23论文数:157被引数:3,149
A
Asuka Okada
H 指数:11论文数:105被引数:402
H
Hayato Kawachi
H 指数:16论文数:152被引数:1,118
M
Masahiro Iwasaku
H 指数:24论文数:135被引数:1,896
N
Naoya Nishioka
H 指数:15论文数:107被引数:1,302
A
Akira Nakao
H 指数:21论文数:139被引数:1,347